Prevention of ventricular fibrillation, acute myocardial infarction (myocardial necrosis), heart failure, and mortality by bretylium: is ischemic heart disease primarily adrenergic cardiovascular disease?

American journal of therapeutics

Volumn 11, Issue 5, 2004, Pages 366-411

  Bacaner, Marvin ^a   Brietenbucher, James ^a   LaBree, John ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; ANTIARRHYTHMIC AGENT; BRETYLIUM;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTI-ARRHYTHMIA AGENTS; BRETYLIUM COMPOUNDS; HEART DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC; VENTRICULAR FIBRILLATION;

EID: 15944392526     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000126444.24163.81     Document Type: Review

References (264)